# DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

> **NCT02197169** · PHASE1 · COMPLETED · sponsor: **DNAtrix, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Glioblastoma or Gliosarcoma

## Interventions

- **DRUG:** Single intratumoral injection of DNX-2401
- **DRUG:** Interferon-gamma

## Key facts

- **NCT ID:** NCT02197169
- **Lead sponsor:** DNAtrix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-11
- **Primary completion:** 2018-03-15
- **Final completion:** 2018-03-15
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02197169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02197169, "DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02197169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*